BioVie Invited To Present Late-Breaking Oral Presentation At The 4th Long Covid International Conference, November 12-13

Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share the presentation titled "Bezisterim Improves Fatigue, Post-Exertional Malaise, and Cognition in Prespecified High-Symptom-Burden Subgroups of the Phase 2 Randomized ADDRESS-LC Trial in Long COVID" during the "Session 8: Clinical Trials" session, starting 3:30 p.m. on Friday, November 13. The presentation will include new biomarker data that has not been shared previously.

The ADDRESS-LC trial, a randomized, placebo-controlled signal seeking, exploratory study, showed treatment with bezisterim showed a consistent trend toward improvement across most patient-reported and objective efficacy measures compared with placebo. In pre-specified, exploratory analyses, patients with more severe baseline fatigue, post-exertional malaise (PEM), or objective cognitive impairment – symptoms affecting approximately 78% of trial participants in at least one domain – experienced the greatest benefits with bezisterim, including statistically significant improvements in multiple measures corresponding to their most pronounced symptoms.

"We look forward to presenting initial biomarker data at the upcoming Long COVID conference that are consistent with the clinical findings observed in ADDRESS-LC," said Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID. "The biomarkers provide further biological support for the potential of bezisterim in treating Long COVID. Our Trial observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognition function among patients with greater baseline symptom burden."